Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia
BMC Neuroscience March 5, 2015 Ludmyla Kandratavicius, Priscila Alves Balista, Daniele C. Wolf et al. 40 citations
Nitric oxide donors, especially sodium nitroprusside (SNP), show promise for treating schizophrenia. In a rat model using ketamine to induce schizophrenia-like behaviors, SNP given either before or after ketamine consistently reduced hyperlocomotion. Glyceryl trinitrate and SNP given after ketamine improved long-term memory, while methylene blue given before ketamine also improved long-term memory. The effects depended on whether the drug was administered before or after ketamine, suggesting the timing of treatment matters. These findings indicate that nitric oxide modulation could be a new pharmacological approach for schizophrenia.